Announcement • Apr 23
Shanghai MicroPort Endovascular MedTech Co., Ltd., Annual General Meeting, May 13, 2026 Shanghai MicroPort Endovascular MedTech Co., Ltd., Annual General Meeting, May 13, 2026, at 13:30 China Standard Time. Location: The Company's Meeting Room, Shanghai China Major Estimate Revision • Apr 08
Consensus EPS estimates increase by 11%, revenue downgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from CN¥1.68b to CN¥1.57b. EPS estimate rose from CN¥4.69 to CN¥5.22. Net income forecast to grow 13% next year vs 30% growth forecast for Medical Equipment industry in China. Consensus price target of CN¥127 unchanged from last update. Share price was steady at CN¥104 over the past week. Announcement • Mar 30
Shanghai MicroPort Endovascular MedTech Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026 Shanghai MicroPort Endovascular MedTech Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026 Reported Earnings • Mar 04
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥4.65 (up from CN¥4.07 in FY 2024). Revenue: CN¥1.35b (up 12% from FY 2024). Net income: CN¥563.2m (up 12% from FY 2024). Profit margin: 42% (in line with FY 2024). Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 7.5%. Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Dec 26
Shanghai MicroPort Endovascular MedTech Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026 Shanghai MicroPort Endovascular MedTech Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026 New Risk • Oct 30
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 30% Last year net profit margin: 52% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (277% cash payout ratio). Profit margins are more than 30% lower than last year (30% net profit margin). Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: CN¥0.98 (vs CN¥1.22 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.98 (down from CN¥1.22 in 3Q 2024). Revenue: CN¥300.4m (up 65% from 3Q 2024). Net income: CN¥114.4m (down 24% from 3Q 2024). Profit margin: 38% (down from 82% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Shanghai MicroPort Endovascular MedTech Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025 Shanghai MicroPort Endovascular MedTech Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 Price Target Changed • Aug 19
Price target increased by 9.4% to CN¥132 Up from CN¥120, the current price target is an average from 4 analysts. New target price is 13% above last closing price of CN¥117. Stock is up 40% over the past year. The company is forecast to post earnings per share of CN¥5.15 for next year compared to CN¥4.07 last year. Buy Or Sell Opportunity • Aug 11
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 37% to CN¥118. The fair value is estimated to be CN¥96.08, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 14%. Revenue is forecast to grow by 64% in 2 years. Earnings are forecast to grow by 84% in the next 2 years. Announcement • Jun 30
Shanghai MicroPort Endovascular MedTech Co., Ltd. to Report First Half, 2025 Results on Aug 27, 2025 Shanghai MicroPort Endovascular MedTech Co., Ltd. announced that they will report first half, 2025 results on Aug 27, 2025 Reported Earnings • May 05
First quarter 2025 earnings released: EPS: CN¥1.05 (vs CN¥1.50 in 1Q 2024) First quarter 2025 results: EPS: CN¥1.05 (down from CN¥1.50 in 1Q 2024). Revenue: CN¥332.2m (down 7.2% from 1Q 2024). Net income: CN¥129.6m (down 30% from 1Q 2024). Profit margin: 39% (down from 52% in 1Q 2024). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Major Estimate Revision • Apr 23
Consensus EPS estimates increase by 20% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from CN¥1.41b to CN¥1.52b. EPS estimate increased from CN¥4.53 to CN¥5.45 per share. Net income forecast to grow 32% next year vs 39% growth forecast for Medical Equipment industry in China. Consensus price target of CN¥121 unchanged from last update. Share price was steady at CN¥86.50 over the past week. Major Estimate Revision • Apr 10
Consensus EPS estimates fall by 23% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥1.49b to CN¥1.41b. EPS estimate also fell from CN¥5.89 per share to CN¥4.53 per share. Net income forecast to grow 17% next year vs 56% growth forecast for Medical Equipment industry in China. Consensus price target broadly unchanged at CN¥121. Share price fell 8.5% to CN¥89.24 over the past week. Major Estimate Revision • Apr 04
Consensus EPS estimates fall by 29% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from CN¥6.74 to CN¥4.80 per share. Revenue forecast steady at CN¥1.49b. Net income forecast to grow 27% next year vs 57% growth forecast for Medical Equipment industry in China. Consensus price target of CN¥122 unchanged from last update. Share price rose 5.7% to CN¥97.52 over the past week. Buy Or Sell Opportunity • Mar 31
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 18% to CN¥90.11. The fair value is estimated to be CN¥113, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 85% in 2 years. Earnings are forecast to grow by 87% in the next 2 years. Announcement • Mar 29
Shanghai MicroPort Endovascular MedTech Co., Ltd., Annual General Meeting, Apr 18, 2025 Shanghai MicroPort Endovascular MedTech Co., Ltd., Annual General Meeting, Apr 18, 2025, at 13:30 China Standard Time. Location: The Company's Meeting Room, Shanghai China Announcement • Mar 28
Shanghai MicroPort Endovascular MedTech Co., Ltd. to Report Q1, 2025 Results on Apr 30, 2025 Shanghai MicroPort Endovascular MedTech Co., Ltd. announced that they will report Q1, 2025 results on Apr 30, 2025 Reported Earnings • Mar 02
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥4.04. Revenue: CN¥1.21b (up 1.6% from FY 2023). Net income: CN¥497.9m (up 1.1% from FY 2023). Profit margin: 41% (in line with FY 2023). Revenue missed analyst estimates by 5.9%. Earnings per share (EPS) also missed analyst estimates by 23%. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in China. Announcement • Dec 27
Shanghai MicroPort Endovascular MedTech Co., Ltd. to Report Fiscal Year 2024 Results on Mar 29, 2025 Shanghai MicroPort Endovascular MedTech Co., Ltd. announced that they will report fiscal year 2024 results on Mar 29, 2025 Price Target Changed • Dec 14
Price target decreased by 7.4% to CN¥122 Down from CN¥132, the current price target is an average from 5 analysts. New target price is 5.2% above last closing price of CN¥116. Stock is down 7.6% over the past year. The company is forecast to post earnings per share of CN¥5.21 for next year compared to CN¥4.57 last year. Valuation Update With 7 Day Price Move • Dec 11
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥117, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Medical Equipment industry in China. Total loss to shareholders of 26% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥103 per share. Major Estimate Revision • Nov 09
Consensus revenue estimates fall by 21% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥1.48b to CN¥1.18b. EPS estimate fell from CN¥5.51 to CN¥5.22 per share. Net income forecast to grow 5.5% next year vs 59% growth forecast for Medical Equipment industry in China. Consensus price target broadly unchanged at CN¥132. Share price rose 5.6% to CN¥104 over the past week. Major Estimate Revision • Nov 05
Consensus revenue estimates decrease by 23%, EPS upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from CN¥1.52b to CN¥1.17b. EPS estimate increased from CN¥5.26 to CN¥5.80 per share. Net income forecast to grow 5.6% next year vs 59% growth forecast for Medical Equipment industry in China. Consensus price target of CN¥130 unchanged from last update. Share price was steady at CN¥102 over the past week. Reported Earnings • Nov 02
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: EPS: CN¥1.22 (up from CN¥1.02 in 3Q 2023). Revenue: CN¥182.4m (down 32% from 3Q 2023). Net income: CN¥149.8m (up 38% from 3Q 2023). Profit margin: 82% (up from 41% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 51%. Earnings per share (EPS) also missed analyst estimates by 19%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to CN¥101, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 19x in the Medical Equipment industry in China. Total loss to shareholders of 35% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥135 per share. Buy Or Sell Opportunity • Oct 11
Now 24% undervalued Over the last 90 days, the stock has risen 7.7% to CN¥103. The fair value is estimated to be CN¥134, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 23%. Revenue is forecast to grow by 60% in 2 years. Earnings are forecast to grow by 47% in the next 2 years. Announcement • Sep 30
Shanghai MicroPort Endovascular MedTech Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Shanghai MicroPort Endovascular MedTech Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024 New Risk • Sep 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (93% cash payout ratio). Share price has been volatile over the past 3 months (6.7% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥94.98, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 18x in the Medical Equipment industry in China. Total loss to shareholders of 46% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥134 per share. Price Target Changed • Sep 23
Price target decreased by 13% to CN¥135 Down from CN¥155, the current price target is an average from 5 analysts. New target price is 70% above last closing price of CN¥79.81. Stock is down 36% over the past year. The company is forecast to post earnings per share of CN¥5.26 for next year compared to CN¥4.57 last year. Reported Earnings • Aug 27
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2024 results: EPS: CN¥1.77 (up from CN¥1.44 in 2Q 2023). Revenue: CN¥429.1m (up 28% from 2Q 2023). Net income: CN¥219.2m (up 42% from 2Q 2023). Profit margin: 51% (up from 46% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 16%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Aug 22
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥80.27, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 17x in the Medical Equipment industry in China. Total loss to shareholders of 55% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥107 per share. Buy Or Sell Opportunity • Aug 20
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 29% to CN¥83.25. The fair value is estimated to be CN¥107, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 66% in 2 years. Earnings are forecast to grow by 57% in the next 2 years. Board Change • Aug 02
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 2 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). GM & Director Qing Zhu is the most experienced director on the board, commencing their role in 2018. Independent Director Xiaojie Ye was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Announcement • Jul 24
Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHSE:688016) announces an Equity Buyback for CNY 100 million worth of its shares. Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHSE:688016) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The repurchase price will not more than CNY 130 per Share. The repurchased shares will be used for employee stock ownership plan or equity incentives. The repurchases will be funded using company's own funds. The repurchase period will be not more than 12 months. Announcement • Jun 28
Shanghai MicroPort Endovascular MedTech Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024 Shanghai MicroPort Endovascular MedTech Co., Ltd. announced that they will report first half, 2024 results on Aug 27, 2024 Reported Earnings • Apr 28
First quarter 2024 earnings: EPS and revenues exceed analyst expectations First quarter 2024 results: EPS: CN¥2.23 (up from CN¥1.73 in 1Q 2023). Revenue: CN¥358.1m (up 25% from 1Q 2023). Net income: CN¥184.3m (up 48% from 1Q 2023). Profit margin: 52% (up from 44% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 42%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Apr 23
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 1.5% to CN¥176. The fair value is estimated to be CN¥146, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Earnings per share has grown by 22%. For the next 3 years, revenue is forecast to grow by 24% per annum. Earnings are also forecast to grow by 25% per annum over the same time period. Announcement • Mar 29
Shanghai MicroPort Endovascular MedTech Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Shanghai MicroPort Endovascular MedTech Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Announcement • Mar 28
Shanghai MicroPort Endovascular MedTech Co., Ltd., Annual General Meeting, Apr 18, 2024 Shanghai MicroPort Endovascular MedTech Co., Ltd., Annual General Meeting, Apr 18, 2024, at 13:30 China Standard Time. Location: The Company's Meeting Room, Shanghai China Reported Earnings • Mar 28
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2023 results: EPS: CN¥6.81 (up from CN¥4.96 in FY 2022). Revenue: CN¥1.19b (up 32% from FY 2022). Net income: CN¥492.4m (up 38% from FY 2022). Profit margin: 42% (up from 40% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) exceeded analyst estimates by 3.8%. Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Mar 28
Now 24% overvalued Over the last 90 days, the stock has fallen 6.7% to CN¥182. The fair value is estimated to be CN¥147, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 69% in 2 years. Earnings are forecast to grow by 63% in the next 2 years. Reported Earnings • Feb 24
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2023 results: EPS: CN¥6.81 (up from CN¥4.96 in FY 2022). Revenue: CN¥1.19b (up 32% from FY 2022). Net income: CN¥492.4m (up 38% from FY 2022). Profit margin: 42% (up from 40% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) exceeded analyst estimates by 3.8%. Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥178, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 21x in the Medical Equipment industry in China. Total loss to shareholders of 38% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥161 per share. Buy Or Sell Opportunity • Feb 07
Now 20% overvalued Over the last 90 days, the stock has fallen 11% to CN¥179. The fair value is estimated to be CN¥149, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 29% over the last 3 years. Earnings per share has grown by 23%. Revenue is forecast to grow by 71% in 2 years. Earnings are forecast to grow by 70% in the next 2 years. Announcement • Jan 30
Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. Provides Earnings Guidance for the Year Ended 31 December 2023 Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. provided earnings guidance for the year ended 31 December 2023. For the year, the company expects operating revenue to be between RMB 1,174.4155 million and RMB 1,201.3105 million, representing an increase of between 31% and 34% as compared with 2022. Net profit attributable to the equity owners to be between RMB 474.6484 million and RMB 492.4923 million, representing an increase of between 33% and 38% as compared with 2022. Net profit attributable to equity owners after deducting non-recurring gains or losses to be between RMB 430.6461 million and RMB 453.3116 million, representing an increase of between 33% and 40% as compared with 2022. Announcement • Dec 29
Shanghai MicroPort Endovascular MedTech Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024 Shanghai MicroPort Endovascular MedTech Co., Ltd. announced that they will report fiscal year 2023 results on Mar 28, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings: EPS misses analyst expectations Third quarter 2023 results: EPS: CN¥1.52 (up from CN¥1.19 in 3Q 2022). Revenue: CN¥266.8m (up 30% from 3Q 2022). Net income: CN¥108.9m (up 27% from 3Q 2022). Profit margin: 41% (down from 42% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.8%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. New Risk • Aug 26
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 71% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (71% accrual ratio). Minor Risk Dividend is not well covered by cash flows (dividend per share is over 7x cash flows per share). Reported Earnings • Jul 30
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Second quarter 2023 results: EPS: CN¥2.16 (up from CN¥1.27 in 2Q 2022). Revenue: CN¥336.0m (up 67% from 2Q 2022). Net income: CN¥155.1m (up 69% from 2Q 2022). Profit margin: 46% (in line with 2Q 2022). Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 20%. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Major Estimate Revision • Apr 06
Consensus EPS estimates fall by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CN¥1.21b to CN¥1.18b. EPS estimate also fell from CN¥7.69 per share to CN¥6.83 per share. Net income forecast to grow 38% next year vs 36% growth forecast for Medical Equipment industry in China. Consensus price target down from CN¥260 to CN¥249. Share price rose 2.2% to CN¥176 over the past week. Price Target Changed • Mar 26
Price target increased by 7.6% to CN¥261 Up from CN¥243, the current price target is an average from 2 analysts. New target price is 52% above last closing price of CN¥172. Stock is down 18% over the past year. The company is forecast to post earnings per share of CN¥7.48 for next year compared to CN¥4.96 last year. Reported Earnings • Mar 02
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥4.96 (up from CN¥4.39 in FY 2021). Revenue: CN¥896.5m (up 31% from FY 2021). Net income: CN¥356.9m (up 13% from FY 2021). Profit margin: 40% (down from 46% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 9.2%. Revenue is forecast to grow 29% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Announcement • Jan 21
Shanghai MicroPort Endovascular MedTech Co., Ltd. Provides Earnings Guidance for the Year Ended 31 December 2022 Shanghai MicroPort Endovascular MedTech Co., Ltd. provided earnings guidance for the year ended 31 December 2022. For the year ended 31 December 2022, the revenue of EV MedTech is expected to be between RMB 855.7907 million and RMB 924.2507 million, representing an increase of between 25% and 35% as compared with 2021. The net profit attributable to the equity owners of EV MedTech is expected to be between RMB 347.4413 million and RMB 379.0268 million, representing an increase of between 10% and 20% as compared with 2021. The net profit attributable to equity owners of EV MedTech after deducting extraordinary gains or losses is expected to be between RMB 317.3023 million and RMB 346.1479 million, representing an increase of between 10% and 20% as compared with 2021. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. Director Liefeng Qu was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Oct 30
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Third quarter 2022 results: EPS: CN¥1.19 (up from CN¥0.90 in 3Q 2021). Revenue: CN¥205.4m (up 39% from 3Q 2021). Net income: CN¥85.8m (up 32% from 3Q 2021). Profit margin: 42% (down from 44% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 4.2%. Earnings per share (EPS) also missed analyst estimates by 22%. Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment improved over the past week After last week's 39% share price gain to CN¥211, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 26x in the Medical Equipment industry in China. Total returns to shareholders of 44% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥122 per share. Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥159, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 22x in the Medical Equipment industry in China. Total returns to shareholders of 24% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥134 per share. Reported Earnings • Aug 26
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Second quarter 2022 results: EPS: CN¥1.27 (up from CN¥1.16 in 2Q 2021). Revenue: CN¥200.9m (up 22% from 2Q 2021). Net income: CN¥91.6m (up 10% from 2Q 2021). Profit margin: 46% (down from 50% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 9.7%. Earnings per share (EPS) also missed analyst estimates by 3.8%. Over the next year, revenue is forecast to grow 42%, compared to a 26% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jul 27
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥153, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 23x in the Medical Equipment industry in China. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥121 per share. Announcement • Jul 26
Shanghai MicroPort Endovascular MedTech Co., Ltd. announced that it expects to receive CNY 2.5468393 billion in funding Shanghai MicroPort Endovascular MedTech Co., Ltd. announced a private placement of not more than 21,593,444 A shares for gross proceeds of not more than CNY 2,546,839,300 on July 25, 2022. The transaction will include participation form not more than 35 investors. The issuance price is not less than 80% of the average price in the 20 trading days before the pricing reference date. The shares cannot be transferred within 6 months from the issuance closing date. The transaction has been approved by the board of directors of the company at its 9th Meeting of the Company’s 2nd Directorate held on July 25, 2022, and is subject to the approvals of the Company’s Shareholders, the Shanghai Stock Exchange, and the China Securities Regulatory Commission.
The Company approved the 2022 private placement of A shares in the 9th Meeting of the 2nd Directorate and the 6th Meeting of the 2nd Supervisory Board. Valuation Update With 7 Day Price Move • Jul 13
Investor sentiment deteriorated over the past week After last week's 19% share price decline to CN¥169, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 21x in the Medical Equipment industry in China. Total loss to shareholders of 56% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥121 per share. Valuation Update With 7 Day Price Move • Jun 02
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥197, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 22x in the Medical Equipment industry in China. Total loss to shareholders of 48% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥121 per share. Price Target Changed • May 04
Price target decreased to CN¥243 Down from CN¥271, the current price target is an average from 5 analysts. New target price is 52% above last closing price of CN¥160. Stock is down 52% over the past year. The company is forecast to post earnings per share of CN¥5.99 for next year compared to CN¥4.39 last year. Reported Earnings • May 02
First quarter 2022 earnings: EPS exceeds analyst expectations First quarter 2022 results: EPS: CN¥1.72 (up from CN¥1.41 in 1Q 2021). Revenue: CN¥257.9m (up 31% from 1Q 2021). Net income: CN¥123.5m (up 21% from 1Q 2021). Profit margin: 48% (down from 52% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 13%. Over the next year, revenue is forecast to grow 39%, compared to a 26% growth forecast for the industry in China. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Apr 01
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: CN¥4.39 (up from CN¥2.98 in FY 2020). Revenue: CN¥684.6m (up 46% from FY 2020). Net income: CN¥316.1m (up 47% from FY 2020). Profit margin: 46% (in line with FY 2020). Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) also surpassed analyst estimates by 3.8%. Over the next year, revenue is forecast to grow 40%, compared to a 25% growth forecast for the industry in China. Valuation Update With 7 Day Price Move • Mar 23
Investor sentiment improved over the past week After last week's 25% share price gain to CN¥219, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 23x in the Medical Equipment industry in China. Total loss to shareholders of 20% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥372 per share. Reported Earnings • Feb 28
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: CN¥4.39 (up from CN¥2.98 in FY 2020). Revenue: CN¥684.6m (up 46% from FY 2020). Net income: CN¥316.1m (up 47% from FY 2020). Profit margin: 46% (in line with FY 2020). Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) also surpassed analyst estimates by 3.8%. Over the next year, revenue is forecast to grow 37%, compared to a 24% growth forecast for the industry in China. Price Target Changed • Feb 26
Price target decreased to CN¥364 Down from CN¥397, the current price target is an average from 4 analysts. New target price is 69% above last closing price of CN¥215. Stock is down 20% over the past year. The company is forecast to post earnings per share of CN¥4.23 for next year compared to CN¥2.98 last year. Announcement • Jan 25
Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2021 Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. provided earnings guidance for the year ended December 31, 2021. The net profit attributable to the equity owners of EV MedTech for the year ended 31 December 2021 is expected to be between RMB 300.46 million and RMB 321.92 million, representing an increase of between 40% and 50% as compared with 2020. The net profit attributable to equity owners of EV MedTech after deducting extraordinary gains or losses is expected to be between RMB 276.85 million and RMB 295.94 million, representing an increase of between 45% and 55% as compared with 2020. The main reason for the increase in profit was that in 2021, although there had been a recurrence of the COVID-19 epidemic, which to a certain degree impacted on the carrying out of surgical operations, the innovative products of EV MedTech, including Castor ® Branched Aortic Stent-Graft System, Minos Abdominal Aortic Stent-Graft and Delivery System and Reewarm PTX Drug Coated Balloon PTA Catheter have all continued rapid growth in 2021. These products have further consolidated and enhanced the competitiveness of EV MedTech in the aortic and peripheral interventional market. At the same time, with the continuous expansion of EV MedTech's innovative products in the international market, revenue from the overseas business has also achieved rapid growth. Valuation Update With 7 Day Price Move • Sep 22
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥282, the stock trades at a forward P/E ratio of 57x. Average forward P/E is 33x in the Medical Equipment industry in China. Total returns to shareholders of 5.2% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥289 per share. Reported Earnings • Aug 26
Second quarter 2021 earnings released: EPS CN¥1.16 (vs CN¥0.84 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: CN¥164.8m (up 43% from 2Q 2020). Net income: CN¥83.0m (up 36% from 2Q 2020). Profit margin: 50% (down from 53% in 2Q 2020). The decrease in margin was driven by higher expenses. Announcement • Jul 20
Shanghai Microport Endovascular Medtech Co., Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2021 Shanghai MicroPort Endovascular MedTech Co., Ltd. provided earnings guidance for the six months ended June 30, 2021. For the period, the company expected to be between RMB 182.50 million and RMB 187.50 million, representing an increase of between 51.40% and 55.55% as compared with the same period last year. The net profit attributable to equity owners of EV MedTech after deducting extraordinary gains or losses is expected to be between RMB 177.50 million and RMB 182.50 million, representing an increase of between 62.22% and 66.79% as compared with the same period last year. Reported Earnings • Apr 21
First quarter 2021 earnings released: EPS CN¥1.41 (vs CN¥0.83 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: CN¥197.5m (up 99% from 1Q 2020). Net income: CN¥101.7m (up 71% from 1Q 2020). Profit margin: 52% (down from 60% in 1Q 2020). The decrease in margin was driven by higher expenses. Reported Earnings • Mar 30
Full year 2020 earnings released: EPS CN¥2.98 (vs CN¥2.31 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥470.3m (up 41% from FY 2019). Net income: CN¥214.6m (up 51% from FY 2019). Profit margin: 46% (up from 43% in FY 2019). The increase in margin was driven by higher revenue. Announcement • Mar 05
Shanghai MicroPort Endovascular MedTech Co., Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021 Shanghai MicroPort Endovascular MedTech Co., Ltd. announced that they will report fiscal year 2020 results on Mar 30, 2021 Reported Earnings • Mar 04
Full year 2020 earnings released: EPS CN¥2.98 (vs CN¥2.31 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥470.3m (up 41% from FY 2019). Net income: CN¥214.6m (up 51% from FY 2019). Profit margin: 46% (up from 43% in FY 2019). The increase in margin was driven by higher revenue. Is New 90 Day High Low • Jan 14
New 90-day high: CN¥303 The company is up 6.0% from its price of CN¥285 on 16 October 2020. The Chinese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥51.49 per share. Is New 90 Day High Low • Nov 06
New 90-day low: CN¥237 The company is down 18% from its price of CN¥289 on 07 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥48.43 per share. Announcement • Jul 10
Shanghai MicroPort Endovascular MedTech Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020 Shanghai MicroPort Endovascular MedTech Co., Ltd. announced that they will report first half, 2020 results on Aug 27, 2020 
